SCYX
SCYNEXIS, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
-1/100
Last price
4.84
▼ 0.19 (3.78%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
4.84
Prev close
5.03
Day high
5.29
Day low
4.79
Volume
162.94K
Market cap
$48.16M
P/E (TTM)
—
52W range
3.53 – 9.12
Day trading desk
Gap from prior close
-3.78%
Prior close 5.03
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
4.84 – 4.84
Position in range
—
—
ATR (14D)
0.45
9.27% of price
Prior day high
5.20
PDH
Prior day low
4.83
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 276.73K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+3.86%
+1.9%
1M
-8.68%
-9.8%
3M
+3.42%
-1.1%
6M
-36.91%
-55.1%
YTD
-4.27%
-18.5%
1Y
-24.37%
-40.8%
3Y
-73.46%
-155.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SCYX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+3.04M
Net buying
Buy transactions
76
3.64M shares
Sell transactions
1
599.00K shares
Net transactions
+77
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
204.26K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 18, 26 | BURKE STEVEN KEITH Director |
STOCK | 5.75K | $0 | Direct |
| Jun 26, 26 | MACDONALD GUY Director |
STOCK | 2.88K | $0 | Direct |
| Jun 26, 26 | TINMOUTH BRIAN PHILIPPE Director |
STOCK | 2.88K | $0 | Direct |
| Jun 26, 26 | ANIDO ARMANDO Director |
STOCK | 2.88K | $0 | Direct |
| Jun 26, 26 | HASTINGS DAVID C Director |
STOCK | 2.88K | $0 | Direct |
| Jun 26, 26 | HANHAM ANN F Director |
STOCK | 2.88K | $0 | Direct |
| Apr 1, 26 | ANGULO GONZALEZ DAVID Chief Executive Officer |
— | 108.69K | — | Direct |
| Jan 29, 26 | ANGULO GONZALEZ DAVID Chief Executive Officer |
— | 391.33K | — | Direct |
| Jan 29, 26 | SUKENICK SCOTT Officer |
— | 129.83K | — | Direct |
| Jan 29, 26 | MACLEOD IVOR Chief Financial Officer |
— | 129.83K | — | Direct |
| Oct 17, 25 | ANGULO GONZALEZ DAVID Chief Executive Officer |
STOCK | 32.50K | $24.70K | Direct |
| Jun 26, 25 | MACDONALD GUY Director |
— | 23.00K | — | Direct |
| Jun 26, 25 | GILMAN STEVEN C Director |
— | 23.00K | — | Direct |
| Jun 26, 25 | TINMOUTH BRIAN PHILIPPE Director |
— | 23.00K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANGULO GONZALEZ DAVID |
Chief Executive Officer | 1.36M | Purchase |
ANIDO ARMANDO |
Director | 11.75K | Stock Award(Grant) |
BURKE STEVEN KEITH |
Director | 5.75K | Stock Award(Grant) |
GILMAN STEVEN C |
Director | 70.00K | Stock Award(Grant) |
HANHAM ANN F |
Director | 11.58K | Stock Award(Grant) |
HASTINGS DAVID C |
Director | 11.52K | Stock Award(Grant) |
MACDONALD GUY |
Director | 12.63K | Stock Award(Grant) |
MACLEOD IVOR |
Chief Financial Officer | 398.53K | Stock Award(Grant) |
SUKENICK SCOTT |
Officer | 574.54K | Stock Award(Grant) |
TINMOUTH BRIAN PHILIPPE |
Director | 12.13K | Stock Award(Grant) |
Fundamentals
Market cap$48.16M
Enterprise value$-3.98M
Revenue (TTM)$19.22M
Gross profit$19.22M
EBITDA—
Net income$-10.23M
EPS (TTM)$-0.89
Free cash flow$-7.32M
Total cash$54.08M
Total debt$1.95M
Book value / share$6.73
Shares outstanding9.95M
Float7.35M
Short % of float4.71%
Dividend yield0.00%
Beta (5Y)1.06
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.09
PEG ratio—
Price / sales—
Price / book0.72
EV / revenue-0.21
EV / EBITDA—
Gross margin100.00%
Operating margin-3308.51%
Profit margin-53.26%
Return on equity-18.38%
Return on assets-20.82%
Debt / equity2.91
Current ratio9.65
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $20.60M | $3.75M | $140.14M | $5.09M | — | +449.9% |
| Operating revenue | $20.60M | $3.75M | $140.14M | $5.09M | — | +449.9% |
| Cost of revenue | — | $0 | $15.62M | $628.00K | $312.00K | — |
| Gross profit | — | $3.75M | $124.52M | $4.46M | $12.85M | — |
| Research & development | $22.28M | $26.41M | $30.93M | $27.26M | — | -15.6% |
| Selling, general & admin | $14.39M | $14.46M | $20.92M | $62.96M | — | -0.4% |
| Total operating expense | $36.67M | $40.86M | $51.85M | $90.22M | — | -10.2% |
| Operating income | -$16.07M | -$37.12M | $72.67M | -$85.76M | — | +56.7% |
| Net interest income | $1.69M | $1.74M | -$2.17M | -$5.37M | — | -2.6% |
| Pre-tax income | -$8.61M | -$21.14M | $67.18M | -$67.51M | — | +59.3% |
| Tax provision | $0 | $151.00K | $138.00K | -$4.70M | — | -100.0% |
| Net income | -$8.61M | -$21.29M | $67.04M | -$62.81M | — | +59.6% |
| Net income to common | -$8.61M | -$21.29M | $67.04M | -$62.81M | — | +59.6% |
| Basic EPS | -1.36 | -3.52 | 11.20 | -11.76 | — | +61.4% |
| Diluted EPS | -1.36 | -3.52 | 11.12 | -11.76 | — | +61.4% |
| EBIT | -$8.44M | -$20.31M | $70.31M | -$62.31M | — | +58.5% |
| EBITDA | -$8.44M | -$20.31M | $70.89M | -$61.70M | — | +58.5% |
| Basic shares | 6.24M | 6.06M | 5.98M | 5.33M | — | +2.9% |
| Diluted shares | 6.24M | 6.06M | 6.05M | 5.33M | — | +2.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $21.26M | $16.05M | $34.05M | $45.81M | — | +32.4% |
| Cash & short-term investments | $40.03M | $59.30M | $74.36M | $73.50M | — | -32.5% |
| Accounts receivable | — | — | $0 | $2.10M | $861.00K | — |
| Inventory | — | — | $0 | $899.00K | $463.00K | — |
| Total current assets | $40.37M | $72.18M | $102.12M | $79.06M | — | -44.1% |
| Property, plant & equipment | $1.76M | $2.09M | $2.36M | $2.59M | — | -15.6% |
| Goodwill & intangibles | — | — | $0 | $408.00K | $1.06M | — |
| Total assets | $59.03M | $90.64M | $128.41M | $87.81M | — | -34.9% |
| Total current liabilities | $5.73M | $24.10M | $16.30M | $17.62M | — | -76.2% |
| Current debt | — | $13.69M | — | — | — | — |
| Long-term debt | — | — | $12.16M | $45.39M | $40.35M | — |
| Total debt | $2.17M | $16.27M | $15.08M | $48.60M | — | -86.6% |
| Total liabilities | $9.65M | $35.57M | $55.45M | $84.58M | — | -72.9% |
| Retained earnings | -$385.14M | -$376.54M | -$355.25M | -$422.29M | — | -2.3% |
| Shareholder equity | $49.38M | $55.08M | $72.96M | $3.23M | — | -10.4% |
| Working capital | $34.64M | $48.08M | $85.81M | $61.44M | — | -28.0% |
| Net tangible assets | $49.38M | $55.08M | $72.96M | $2.83M | — | -10.4% |
| Shares issued | 5.44M | 4.75M | 4.65M | 4.09M | — | +14.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$8.61M | -$21.29M | $67.04M | -$62.81M | — | +59.6% |
| Depreciation & amortisation | — | $0 | $580.00K | $606.00K | $379.00K | — |
| Stock-based compensation | $2.85M | $3.35M | $2.62M | $3.69M | — | -14.8% |
| Change in working capital | $6.08M | $7.28M | -$30.64M | $764.00K | — | -16.5% |
| Operating cash flow | -$5.28M | -$24.01M | $60.16M | -$79.88M | — | +78.0% |
| Capital expenditure | — | — | — | -$9.00K | -$1.17M | — |
| Investing cash flow | $24.31M | $6.15M | -$34.88M | -$27.39M | — | +295.2% |
| Financing cash flow | -$14.17M | -$139.00K | -$36.72M | $48.60M | — | -10,094.2% |
| Free cash flow | -$5.28M | -$24.01M | $60.16M | -$79.89M | — | +78.0% |
| End cash position | $21.45M | $16.59M | $34.59M | $46.03M | — | +29.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $235.00K | $0 | $18.65M | $334.00K | $1.36M | — | — |
| Operating revenue | $235.00K | $0 | $18.65M | $334.00K | $1.36M | — | — |
| Research & development | $3.89M | $12.35M | $4.54M | $5.45M | $7.14M | — | -68.5% |
| Selling, general & admin | $4.12M | $4.59M | $3.58M | $3.29M | $3.78M | — | -10.2% |
| Total operating expense | $8.01M | $16.94M | $8.13M | $8.74M | $10.93M | — | -52.7% |
| Operating income | -$7.78M | -$16.94M | $10.52M | -$8.40M | -$9.56M | — | +54.1% |
| Net interest income | $685.00K | $535.00K | $418.00K | $454.00K | $510.00K | — | +28.0% |
| Pre-tax income | $7.40M | -$21.30M | $12.26M | -$8.59M | -$6.88M | — | +134.7% |
| Tax provision | — | — | $0 | $0 | $0 | $0 | — |
| Net income | $7.40M | -$21.30M | $12.26M | -$8.59M | -$6.88M | — | +134.7% |
| Net income to common | $7.40M | -$21.30M | $12.26M | -$8.59M | -$6.88M | — | +134.7% |
| Basic EPS | 0.63 | -3.36 | — | -1.36 | -1.11 | -0.88 | +118.8% |
| Diluted EPS | 0.63 | -3.36 | — | -1.36 | -1.11 | -0.88 | +118.8% |
| EBIT | $7.40M | -$21.30M | $12.26M | -$8.59M | -$6.88M | — | +134.7% |
| EBITDA | $7.40M | -$21.30M | $12.26M | -$8.59M | -$6.88M | — | +134.7% |
| Basic shares | 11.82M | 6.37M | — | 6.24M | 6.22M | 6.18M | +85.6% |
| Diluted shares | 11.82M | 6.37M | — | 6.24M | 6.22M | 6.18M | +85.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.49M | $36.67M | $21.26M | $14.80M | $11.02M | -71.4% |
| Cash & short-term investments | $54.08M | $59.26M | $40.03M | $37.93M | $44.78M | -8.7% |
| Total current assets | $56.24M | $62.69M | $40.37M | $48.69M | $56.50M | -10.3% |
| Property, plant & equipment | $1.58M | $1.67M | $1.76M | $1.85M | $1.93M | -5.7% |
| Total assets | $74.97M | $77.63M | $59.03M | $51.07M | $60.69M | -3.4% |
| Total current liabilities | $5.83M | $15.90M | $5.73M | $8.47M | $10.86M | -63.4% |
| Total debt | $1.95M | $2.06M | $2.17M | $2.28M | $2.39M | -5.6% |
| Total liabilities | $8.04M | $36.32M | $9.65M | $14.64M | $16.23M | -77.9% |
| Retained earnings | -$399.05M | -$406.44M | -$385.14M | -$397.40M | -$388.81M | +1.8% |
| Shareholder equity | $66.93M | $41.31M | $49.38M | $36.43M | $44.47M | +62.0% |
| Working capital | $50.41M | $46.79M | $34.64M | $40.23M | $45.63M | +7.7% |
| Net tangible assets | $66.93M | $41.31M | $49.38M | $36.43M | $44.47M | +62.0% |
| Shares issued | 9.95M | 7.76M | 5.44M | 5.24M | 4.90M | +28.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $7.40M | -$21.30M | $12.26M | -$8.59M | -$6.88M | +134.7% |
| Stock-based compensation | $568.00K | $580.00K | $687.00K | $526.00K | $820.00K | -2.1% |
| Change in working capital | -$8.86M | $6.56M | $6.75M | -$1.28M | $772.00K | -235.0% |
| Operating cash flow | -$14.88M | -$8.10M | $18.40M | -$8.72M | -$7.50M | -83.7% |
| Investing cash flow | -$24.76M | -$525.00K | -$11.82M | $12.42M | $11.27M | -4,615.8% |
| Financing cash flow | $13.46M | $24.04M | -$115.00K | $29.00K | $0 | -44.0% |
| Free cash flow | -$14.88M | -$8.10M | $18.40M | -$8.72M | -$7.50M | -83.7% |
| End cash position | $10.68M | $36.86M | $21.45M | $14.99M | $11.26M | -71.0% |
Options analytics
Put / call volume
0.25
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
-48.3% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
-6.2%
Calls bid over puts
Call volume
8
Contracts, this expiry
Put volume
2
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
2.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.51 | 0.63 | +224.3% |
| Mar 2026 | -0.99 | -3.36 | -240.5% |
| Dec 2025 | 1.01 | 2.00 | +97.4% |
| Sep 2025 | -1.60 | -1.36 | +15.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.72 | 2 | $98.00K | -70.7% |
| Next quarter | -0.68 | 2 | $977.67K | -94.8% |
| Current year | -2.91 | 2 | $619.50K | -97.0% |
| Next year | -2.32 | 2 | $6.68M | +977.9% |
Analyst targets & ownership
Mean target$36.33
High target$44.00
Low target$32.00
Implied upside650.69%
Analyst count3
ConsensusSTRONG BUY
Strong buy / Buy1 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders2.05%
Held by institutions62.10%
Institutions holding46
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.81
+0.72% from price
SMA 20
4.69
+3.23% from price
SMA 50
4.90
-1.25% from price
SMA 100
4.74
+2.03% from price
SMA 200
5.64
-14.25% from price
EMA 12
4.85
-0.29% from price
EMA 26
4.83
+0.19% from price
EMA 50
4.85
-0.30% from price
RSI (14)
50.2
Neutral
MACD (12,26,9)
0.02
Hist 0.06
ATR (14)
0.45
9.27% of price
Realised vol 30D
73.0%
Annualised
Bollinger upper
5.28
20, 2σ
Bollinger lower
4.10
20, 2σ
50 / 200 cross
Death
4.90 vs 5.64
Trend bias
Below 200
-14.25%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.33
More volatile than market
Correlation to SPY
0.24
Largely independent
Realised vol 30D
73.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-59.8%
Peak to trough
Max drawdown 5Y
-94.2%
Peak to trough
ATR 14
0.45
9.27% of price
Beta (reported)
1.06
5Y monthly, from filing
Short interest
Shares short
459.75K
Prior 417.67K
Change vs prior
+10.1%
Shorts adding
% of float
4.71%
Normal
% of shares out
4.62%
Against total outstanding
Days to cover
6.8
Crowded exit
Float
7.35M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Oct 28, 25 | Guggenheim | MAINTAINED | Buy | Buy |
| Apr 1, 24 | Cantor Fitzgerald | MAINTAINED | — | Overweight |
| Aug 15, 23 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Apr 3, 23 | Guggenheim | MAINTAINED | — | Buy |
| Apr 3, 23 | Ladenburg Thalmann | MAINTAINED | — | Buy |
| Mar 1, 23 | Guggenheim | INITIATED | — | Buy |
| May 13, 22 | HC Wainwright & Co. | MAINTAINED | — | Buy |
| Mar 31, 22 | HC Wainwright & Co. | MAINTAINED | — | Buy |
| Jun 7, 21 | Aegis Capital | MAINTAINED | — | Buy |
| Apr 12, 21 | Aegis Capital | MAINTAINED | — | Buy |
| Jan 22, 21 | Guggenheim | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateJul 17, 2020
Last split1:8
Split dateJun 1, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-28
Corporate Changes & Voting Matters
8-K · 2026-09-22
Corporate Changes & Voting Matters
8-K · 2026-09-10
Offering Registrations
S-8 · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-06-26
Corporate Changes & Voting Matters
8-K · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-22
Periodic Financial Reports
10-Q · 2026-05-11
Headlines
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
GlobeNewswire · 22h ago
Scynexis stock surges on $214M BARDA contract for SCY-247
Investing.com · 9d ago
Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract
InvestorsHub · 9d ago
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
GlobeNewswire · 9d ago
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
GlobeNewswire · 15d ago
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
GlobeNewswire · 22d ago
SCYNEXIS Names Sanjay Subramanian as CFO
MT Newswires · 27d ago
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
GlobeNewswire · 27d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.